ENDOSCOPIC SLEEVE GASTROPLASTY (ESG): SHORT-TERM EFFICACY AND SAFETY PROFILE IN A SINGLE CENTER SERIES

Aims ESG has positioned as one of the most promising incisionless techniques to induce gastric volume restriction leading to weight loss in patients with obesity, showing good results within a safe profile.

Methods Outcomes: To describe the efficacy and safety in a cohort of 50 patients elected to ESG in a single center after 6 months of multidisciplinary follow up.

Methods prospective collection of total body weight loss percentage (TBWL%) and BMI decrease along the first 6 months of follow-up after the ESG. All patients were performed by a single endoscopist (AJPG), signed the informed consent and were done under antibiotic prophylaxis, CO2 insufflation and general anesthesia in an inpatient basis. After ruling out contraindications by upper endoscopy, we placed an esophageal overtube and used the Apollo overstitch system Gen-2 device (AOS) attached to a dual channel Olympus gastroscope. We used a Z-shape along the greater curvature to do full-thickness plications with a mean of 4.3 sutures.

Results Efficacy: 50 patients (46F) completed the 6-month schedule (11 nutritional counseling visits); aged 42.9 yo and pre-treatment BMI: 35.6 kg/m2. 96% were discharged in<24 hours . TBWL% at 1, 3, 6 m=9.2%, 15.8% and 19.3%. Post-treatment BMI: 28.8 kg/m2; BMI decrease: 6.8 kg/m2. Safety: 2 adverse events: 1 delayed haemorrhage, a week after the procedure, requiring blood transfusion and endoscopic management; and 1 esophageal hematoma, after overtube placement.

Conclusions ESG showed a remarkable short-term efficacy in our series and a good safety profile and applies as a good alternative for the treatment of obesity

Publication History

Article published online:
14 April 2022